Verastem, Inc. is a biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer.
Scientific cofounder Robert Weinberg, Ph.D., explains the role of cancer stem cells in cancer progression »ANNOUNCEMENTS 
May 14, 2012
Verastem, Inc. Reports First Quarter 2012 Financial Results
April 26, 2012
Verastem to Present at the Deutsche Bank 37th Annual Health Care
Conference
April 12, 2012
Verastem to Present at the BioCentury Future Leaders in the Biotech
Industry Conference
Cancer Stem Cells
The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.
Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells